首页|基于临床应用数据的伏立康唑相关肝损伤风险信号分析

基于临床应用数据的伏立康唑相关肝损伤风险信号分析

扫码查看
目的 基于美国食品药品监督管理局不良事件报告系统(FAERS)数据库,对伏立康唑及其他抗真菌药物肝损伤不良事件信号进行挖掘与对比分析,为临床用药提供参考.方法 提取FAERS数据库2004年1月至2022年3月抗真菌药物的药物不良事件(ADE)信息,以伏立康唑为目标药物,用报告比值比(ROR)法确定风险信号,并与临床常用的其他系统性抗真菌药物进行对比分析.结果 共获得以伏立康唑为主要怀疑药物的肝功能损伤相关ADE 646例次,发生时间中位数为8 d.与数据库中背景药物相比,伏立康唑与肝损伤强相关{ ROR为6.82[95%置信区间(CI)=6.26~7.42]}.与其他抗真菌药物相比,伏立康唑的肝损伤风险均较氟康唑、艾沙康唑和两性霉素B更高,其RORs分别为 2.19(95%CI=1.94~2.47)、2.31(95%CI=1.66~3.22)和 1.26(95%CI=1.08~1.48).伏立康唑肝损伤ADE信号强度前10位的分别为胆汁淤积、肝细胞溶解、混合型肝损伤、胆汁淤积型肝炎、血碱性磷酸酶升高、γ-谷氨酰转移酶增加、肝功能异常、肝细胞损伤、肝功能检查异常及肝脾肿大,且均与伏立康唑强相关(ROR>5).结论 伏立康唑与肝损伤密切相关,提示临床在用药期间应密切关注患者的肝功能指标.抗真菌药物引起肝损伤的风险与患者的基础疾病及药物体内的暴露量密切相关,因此,临床和实验室监测,包括治疗药物监测,对于预防或及时识别肝功能的进一步恶化至关重要.
Analysis of voriconazole-related hepatic dysfunction risk signals based on clinical application data
Objective To mine and conduct comparative analysis for hepatic dysfunction adverse events of voriconazole and other antifungal drugs,based on the Food and Drug Administration Adverse Event Reporting System(FAERS)database,and provide reference for clinical practice.Methods Data from January 2004 to March 2022 in FAERS were retrieved.We estimate the association between the hepatic dysfunction events and voriconazole using reporting odds ratio(ROR)for mining the adverse drug event report signals and compare voriconazole with the full database and other antifungal drugs.Results A total of 646 reports of hepatic dysfunction related to voriconazole as the primary suspect drug were collected totally.The median time to event of the hepatic dysfunction events was 8 d.The overall ROR 95%confidence interval(CI)for hepatic-related adverse drug events was 6.82(95%CI=6.26-7.42).Comparing to other antifungal drugs,voriconazole significantly increased the risk of hepatic dysfunction compared with fluconazole,isavuconazole and amphotericin B,with RORs of 2.19(95%CI=1.94-2.47),2.31(95%CI=1.66-3.22)and 1.26(95%CI=1.08-1.48).The top 10 adverse event signals are cholestasis,hepatic cytolysis,mixed liver injury,hepatitis cholestatic,blood alkaline phosphatase increased,γ-glutamyltransferase increased,hepatic function abnormal,hepatocellular injury,liver function test abnormal and hepatosplenomegaly,and all of them have great correlation with voriconazole(ROR>5).Conclusion Voriconazole is closely related to hepatic dysfunction,indicating that clinical attention should be paid to patients'hepatic function indicators during medication.Since the risk of hepatic dysfunction caused by voriconazole depends on several factors including the underlying disease of the patient and the exposure level of the drugs,close clinical and laboratory monitoring,including therapeutic drug monitoring,are essential to prevent or promptly recognize further deterioration of the hepatic function.

voriconazolehepatic dysfunctioninvasive aspergillosisreal-world studyFood and Drug Administration Adverse Event Reporting System

贠菊平、王梓贺、刘炜

展开 >

首都医科大学附属北京佑安医院药学部,北京 100069

伏立康唑 肝功能异常 侵袭性曲霉菌病 真实世界研究 美国食品药品监督管理局不良反应事件报告系统

2024

中国临床药理学杂志
中国药学会

中国临床药理学杂志

CSTPCD北大核心
影响因子:1.91
ISSN:1001-6821
年,卷(期):2024.40(9)
  • 19